CASSAVA SCIENCES INC-28 (SAVAW) Stock News
NASDAQ:SAVAW - Nasdaq - - Currency: USD
SAVAW Latest News, Press Relases and Analysis
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
All three companies are early-stage biotechnology companies working on next-generation therapeutics with advanced technologies. Over the weekend, Dr. Peter Marks, who headed the FDA's Center for Biologics Evaluation and Research, as well as its vaccine division, resigned in protest.
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon-to-be-discontinued Alzheimer's drug simufilam. U.S. District Judge Jennifer Rochon in Manhattan said Adrian Heilbut, Jesse Brodkin, Enea Milioris, David Bredt and Geoffrey Pitt could try to prove that Cassava knew or should have known that it could not win its defamation lawsuit against them, which it dismissed in August.
New SAVAW Warrants Are Trading After Cassava Sciences’ Distribution
Following a distribution, investors in Cassava Sciences and SAVA stock now have some warrants to factor into their models today.
Mentions: SAVA